MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • 2019 International Congress

    Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease

    D. Grün, V. Zimmer, J. Kauffmann, M. Unger, J. Spiegel, KU. Dillmann, A. Schwiertz, K. Faßbender, M. Fousse (Homburg, Germany)

    Objective: To investigate if we were able to reproduce our previous findings in an independent patient cohort and whether such a correlation also exists in…
  • 2019 International Congress

    Efficacy of opicapone in Parkinson’s disease patients according to baseline rasagiline use: a post-hoc analysis from combined BIPARK-I and II

    A. Lees, J. Ferreira, O. Rascol, W. Poewe, E. Tolosa, H. Gama, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent rasagiline use (CRU). Background: OPC, a once-daily COMT inhibitor,…
  • 2018 International Congress

    Acute efficacy and tolerability of the COMT inhibitor opicapone

    F. Gandor, D. Sykora, D. Gruber, G. Ebersbach (Beelitz-Heilstätten, Germany)

    Objective: Evaluation of the acute efficacy and tolerability of Opicapone. Background: Opicapone is a Catechol-O-Methyltransferase (COMT) inhibitor for the treatment of patients with idiopathic Parkinson’s…
  • 2018 International Congress

    Influence of baseline OFF-time in the efficacy response of opicapone in Parkinson’s disease patients with motor fluctuations: The BIPARK-I double-blind experience

    P. Korlipara, J. Ferreira, H. Gama, A. Santos, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and subdivided by their baseline OFF-time. Background: OPC,…
  • 2018 International Congress

    A novel non-nitrocatechol COMT inhibitor ODM-104 shows superior pharmacodynamic effects to entacapone

    S. Janhunen, J. Venäläinen, J. Kaskinoro, L. Saloranta, J. Tuunainen (Turku, Finland)

    Objective: ODM-104 is a novel non-nitrocatechol catechol-O-methyltransferase (COMT) inhibitor that is undergoing clinical evaluation for Parkinson’s disease (PD). This study investigated the pharmacodynamic effects of…
  • 2018 International Congress

    Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results of the 1-year extension BIPARK-I study

    R. Ehret, J. Ferreira, F. Stocchi, F. Ikedo, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Berlin, Germany)

    Objective: To evaluate the impact on UPDRS-II and III in levodopa-treated Parkinson’s Disease (PD) patients who switched from placebo (PLC) or entacapone (ENT) to opicapone…
  • 2018 International Congress

    Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

    J. Pagonabarraga, E. Tolosa, J. Ferreira, A. Lees, E. Arbe, J. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To elucidate which levodopa-treated COMT-naïve Parkinson’s Disease (PD) patients were at higher risk for developing dyskinesia when starting opicapone (OPC) 50mg or entacapone (ENT).…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Responder analyses from the BIPARK-I double-blind experience

    J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the proportion of patients (ie, responders) achieving at least a 1-h reduction…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: The BIPARK-I double-blind experience

    J. Kulisevsky, E. Tolosa, J. Ferreira, A. Lees, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Barcelona, Spain)

    Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a novel once-daily COMT inhibitor,…
  • 2018 International Congress

    Relationship between Patient Global Impression of Change and other Efficacy Endpoints in Parkinson’s Disease: A post-hoc analysis from combined BIPARK-I and II

    J. Ferreira, W. Poewe, O. Rascol, R. Costa, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: To evaluate the association of patients’ perception of Parkinson’s Disease (PD) symptoms improvement (as assessed by Patient Global Impression of Change, PGIC) could be…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Unusual prolonged survival in multiple system atrophy: A case report
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley